MSB 12.1% 55.5¢ mesoblast limited

Ann: Novartis and Mesoblast Remestemcel-L Collaboration, page-761

  1. 7,125 Posts.
    lightbulb Created with Sketch. 6356
    So were the ARDS results not a huge disappointment in that many of us suspect that a treatment that has merit to the thousands dying has been squandered, but the new SA strain maybe illusive to treatments and vaccines, in that antibodies have less effect on it - a significant aspect of vaccine efficacy. I hope Novartis see something in the ARDS results that perks their interest and they execute a quick C-19 ARDS P3 trial in Europe with MSB (the Dutch for example did a 500+ trial in a month at the height of the crisis in similar patients) for the sake of hunman-kind, not my investment.

    Contrary to market exuberance over vaccines, I think this thing is far from over....
 
watchlist Created with Sketch. Add MSB (ASX) to my watchlist
(20min delay)
Last
55.5¢
Change
0.060(12.1%)
Mkt cap ! $633.0M
Open High Low Value Volume
50.0¢ 59.0¢ 48.5¢ $16.88M 30.80M

Buyers (Bids)

No. Vol. Price($)
7 99223 55.5¢
 

Sellers (Offers)

Price($) Vol. No.
56.0¢ 44000 4
View Market Depth
Last trade - 16.10pm 28/03/2024 (20 minute delay) ?
Last
55.5¢
  Change
0.060 ( 15.7 %)
Open High Low Volume
50.5¢ 59.0¢ 48.5¢ 11524458
Last updated 16.02pm 28/03/2024 ?
MSB (ASX) Chart
arrow-down-2 Created with Sketch. arrow-down-2 Created with Sketch.